POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
POLY ICLC 和 α 干扰素治疗难治性恶性肿瘤
基本信息
- 批准号:3838223
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:clinical trials combination cancer therapy combination chemotherapy dosage double stranded RNA drug adverse effect enzyme induction /repression gene induction /repression human subject human therapy evaluation human tissue hypotension immunomodulators interferon inducers interferons methylcellulose neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy pharmacogenetics poly IC polylysine
项目摘要
Interferon induces the synthesis of a large number of gene products.
These products play a role in the antiviral and antiproliferative effects
of alpha interferon. Two of the induced gene products,
2',5'-oligoadenylate synthetase and the double-stranded inhibitor (DSI)
are induced by interferon but require double-stranded RNA to activate
them. The DSI plays a major role in inhibiting protein synthesis
initiation by phosphorylating the eukaryotic initiation factor 2 (elF-2)
on serine 51 of its alpha subunit.
This study combined administration of interferon alpha and Poly ICLC, a
form of double-stranded RNA, in order to determine the optimal dose level
of interferon for induction of the DSI and the optimal dose of Poly ICLC
for activation of the kinase. Three dose levels of interferon were
combined with one of four dose levels of Poly ICLC.
This study was designed to determine the toxicity of this combination and
the maximal tolerated dose. Dose-limiting toxicity was observed with the
combination of interferon 10 mu/m2 and Poly ICLC 0.03 mg/m2. Toxicity
consisted of prolonged hypotension requiring hospitalization for
intravenous fluid administration. Higher doses of Poly ICLC allowed
administration of interferon at the 10 mu/m2 dose level without this
toxicity. These results suggest that Poly ICLC may be more toxic at
lower doses or that higher doses of ICLC may reduce the toxicity of
interferon.
干扰素诱导大量基因产物的合成。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
J E JANIK其他文献
J E JANIK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('J E JANIK', 18)}}的其他基金
PHASE II EFFICACY STUDY OF ROFERON A IN HAIRY CELL LEUKEMIA
Roferon A 治疗毛细胞白血病的 II 期疗效研究
- 批准号:
2464506 - 财政年份:
- 资助金额:
-- - 项目类别:
RGM-CSF AND HIGH DOSE CARBOPLATIN THERAPY IN REFRACTORY OVARIAN CANCER
RGM-CSF 和高剂量卡铂治疗难治性卵巢癌
- 批准号:
3874539 - 财政年份:
- 资助金额:
-- - 项目类别:
PHASE IB TRIAL OF LEVAMISOLE ALONE AND IN COMBINATION WITH R-INTERFERON GAMMA
单独使用左旋咪唑以及与 R-干扰素 GAMMA 联用的 IB 期试验
- 批准号:
2464513 - 财政年份:
- 资助金额:
-- - 项目类别:
PHASE II EVALUATION OF TOPOTECAN IN MELANOMA AND RENAL CELL CARCINOMA
拓扑替康在黑色素瘤和肾细胞癌中的 II 期评估
- 批准号:
3752507 - 财政年份:
- 资助金额:
-- - 项目类别:
PHASE II EFFICACY STUDY OF ROFERON A (R022-8181/002) IN HAIRY CELL LEUKEMIA
ROFERON A (R022-8181/002) 治疗毛细胞白血病的 II 期疗效研究
- 批准号:
3752481 - 财政年份:
- 资助金额:
-- - 项目类别:
PHASE 1 EVALUATION OF INTRATUMORAL INTERLEUKIN-1 ALPHA
瘤内 INTERLEUKIN-1 ALPHA 的第一阶段评估
- 批准号:
3853339 - 财政年份:
- 资助金额:
-- - 项目类别:
PHASE I EVALUATION OF A MODIFIED HEPATIC ARTERY INFUSION CATHETER
改良肝动脉输注导管的 I 期评估
- 批准号:
3752508 - 财政年份:
- 资助金额:
-- - 项目类别:
PHASE 1 EVALUATION OF INTRATUMORAL INTERLEUKIN-1 ALPHA
瘤内 INTERLEUKIN-1 ALPHA 的第一阶段评估
- 批准号:
3838227 - 财政年份:
- 资助金额:
-- - 项目类别:
PHASE II EVALUATION OF TOPOTECAN IN MELANOMA AND RENAL CELL CARCINOMA
拓扑替康在黑色素瘤和肾细胞癌中的 II 期评估
- 批准号:
3838238 - 财政年份:
- 资助金额:
-- - 项目类别:
相似海外基金
Multifunctional Au/Silk Nanoparticles Prepared by Facile Co-Precipitation Method and Evaluation for Delivery, Imaging and Targeting in Combination Cancer Therapy
简易共沉淀法制备的多功能金/丝纳米粒子及其在癌症联合治疗中的递送、成像和靶向评估
- 批准号:
19K15388 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Co-inhibition of adenosine generation and signalling: a new combination cancer therapy
腺苷生成和信号传导的共同抑制:一种新的组合癌症疗法
- 批准号:
nhmrc : GNT1120887 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Project Grants
Co-inhibition of adenosine generation and signalling: a new combination cancer therapy
腺苷生成和信号传导的共同抑制:一种新的组合癌症疗法
- 批准号:
nhmrc : 1120887 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Project Grants
Development of a combination cancer therapy utilizing oncolytic adenovirus with chemotherapy
利用溶瘤腺病毒与化疗联合开发癌症疗法
- 批准号:
15K20381 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Young Scientists (B)
Targeting nucleotide excision repair in combination cancer therapy
联合癌症治疗中的靶向核苷酸切除修复
- 批准号:
8652165 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Targeting nucleotide excision repair in combination cancer therapy
联合癌症治疗中的靶向核苷酸切除修复
- 批准号:
8898026 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Targeting nucleotide excision repair in combination cancer therapy
联合癌症治疗中的靶向核苷酸切除修复
- 批准号:
8743197 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Multiscale computational models for developing combination cancer therapy
用于开发癌症联合疗法的多尺度计算模型
- 批准号:
8323312 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Multiscale computational models for developing combination cancer therapy
用于开发癌症联合疗法的多尺度计算模型
- 批准号:
8692916 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Multiscale computational models for developing combination cancer therapy
用于开发癌症联合疗法的多尺度计算模型
- 批准号:
8098464 - 财政年份:2011
- 资助金额:
-- - 项目类别: